MANKIND - Swing Trade Analysis with AI Signals
Back to List📊 Swing Trade Rating: 3.8
| Stock Code | MANKIND | Market Cap | 93,215 Cr. | Current Price | 2,258 ₹ | High / Low | 2,727 ₹ |
| Stock P/E | 52.8 | Book Value | 376 ₹ | Dividend Yield | 0.04 % | ROCE | 15.0 % |
| ROE | 13.9 % | Face Value | 1.00 ₹ | DMA 50 | 2,147 ₹ | DMA 200 | 2,245 ₹ |
| Chg in FII Hold | -1.10 % | Chg in DII Hold | 1.20 % | PAT Qtr | 513 Cr. | PAT Prev Qtr | 459 Cr. |
| RSI | 65.0 | MACD | 50.1 | Volume | 1,67,469 | Avg Vol 1Wk | 2,62,637 |
| Low price | 1,910 ₹ | High price | 2,727 ₹ | PEG Ratio | 6.27 | Debt to equity | 0.47 |
| 52w Index | 42.6 % | Qtr Profit Var | 24.5 % | EPS | 41.3 ₹ | Industry PE | 30.2 |
Analysis: Mankind Pharma is trading at 2,258 ₹, above its 50 DMA (2,147 ₹) and near its 200 DMA (2,245 ₹), showing short-term strength. RSI at 65.0 and MACD at 50.1 indicate bullish momentum but nearing overbought territory. The stock is well below its 52-week high of 2,727 ₹, leaving room for upside. Valuation is stretched with a P/E of 52.8 compared to the industry average of 30.2, while ROCE (15.0%) and ROE (13.9%) are moderate. Quarterly PAT growth (513 Cr vs 459 Cr) and EPS at 41.3 ₹ reflect earnings improvement. However, the PEG ratio of 6.27 suggests poor valuation relative to growth, and debt-to-equity ratio at 0.47 adds some leverage risk. Institutional activity shows FII holdings decreased (-1.10%), while DIIs increased (+1.20%), balancing sentiment.
Optimal Entry Price: Around 2,200–2,220 ₹ (near 50 DMA support zone).
Exit Strategy: If already holding, consider exiting near 2,700–2,720 ₹ (recent high resistance zone) or if RSI crosses 70. A stop-loss can be placed around 2,150 ₹ to manage downside risk.
✅ Positive
- Quarterly PAT growth (513 Cr vs 459 Cr).
- EPS at 41.3 ₹, reflecting earnings strength.
- DII holdings increased (+1.20%).
- Stock trading above both 50 DMA and 200 DMA, confirming uptrend.
⚠️ Limitation
- High P/E ratio (52.8) compared to industry average.
- PEG ratio at 6.27, suggesting poor valuation relative to growth.
- Debt-to-equity ratio at 0.47, showing moderate leverage.
- Volume below weekly average, limiting momentum.
📉 Company Negative News
- FII holdings decreased (-1.10%).
- Stock trading far below 52-week high (2,727 ₹).
📈 Company Positive News
- Quarterly profit growth of 24.5% variation.
- DII holdings increased (+1.20%), showing domestic institutional support.
🏭 Industry
- Industry P/E at 30.2, much lower than Mankind Pharma, highlighting overvaluation.
- Pharmaceutical sector remains resilient with steady demand and global expansion opportunities.
🔎 Conclusion
Mankind Pharma is a moderately suitable candidate for swing trading, supported by earnings growth and institutional support. Entry near 2,200–2,220 ₹ is optimal, with exit around 2,700–2,720 ₹. Risk management is essential due to stretched valuations, high PEG ratio, and resistance near the 52-week high.